Article
Sponsored Content
Shortening the Rare Disease Diagnostic Odyssey
Author(s):
Specialty and rare diseases have undefined patient populations with patients who are undiagnosed or misdiagnosed, healthcare providers who are unaware of disease states and their manifestations, as well as diagnostic and treatment journeys that are not well-understood. By applying artificial intelligence and machine learning to real world data, pharmaceutical companies can improve outcomes at scale.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Related Content
